Exchange: NASDAQ·Updated 07:46 PM EDT

AQST News

News
all
press releases
Aquestive Therapeutics, Inc. (Nasdaq: AQST) Investor Alert: Schubert Jonckheer Investigating Possible False Statements Following 37% Stock Drop
Aquestive Therapeutics, Inc. (Nasdaq: AQST) Investor Alert: Schubert Jonckheer Investigating Possible False Statements Following 37% Stock Drop Aquestive Therapeutics, Inc. (Nasdaq: AQST) Investor Alert: Schubert Jonckheer Investigating Possible False Statements Following 37% Stock DropPR...
PR Newswire
Aquestive Therapeutics, Inc. (Nasdaq: AQST) Investor Alert: Schubert Jonckheer Investigating Possible False Statements Following 37% Stock Drop
Aquestive Therapeutics, Inc. (Nasdaq: AQST) Investor Alert: Schubert Jonckheer Investigating Possible False Statements Following 37% Stock Drop Aquestive Therapeutics, Inc. (Nasdaq: AQST) Investor Alert: Schubert Jonckheer Investigating Possible False Statements Following 37% Stock DropPR...
PR Newswire
More News
Aquestive Therapeutics Resubmits NDA For Anaphylm Sublingual Film
(RTTNews) - Aquestive Therapeutics (AQST) announced that it has resubmitted its New Drug Application to the FDA for Anaphylm sublingual film for the treatment of Type I allergic reactions, including anaphylaxis. The company said the resubmission is supported by positive topline h...
Nasdaq News: Markets
Aquestive Therapeutics Q2 Earnings Call Highlights
Aquestive Therapeutics Q2 Earnings Call Highlights...
Yahoo! Finance: News
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -80.00% and +12.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study
Aquestive Therapeutics reports positive study results for Anaphylm sublingual film, paving the way for a Q3 FDA resubmission.read more...
Benzinga
Guardian Pharmacy Services (GRDN) Q2 Earnings and Revenues Top Estimates
Guardian Pharmacy (GRDN) delivered earnings and revenue surprises of +11.54% and +3.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock?
Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?
Aquestive Therapeutics (AQST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
Aquestive Therapeutics Q1 Earnings Call Highlights
Aquestive Therapeutics Q1 Earnings Call Highlights...
Yahoo! Finance: News
Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Aquestive Therapeutics (AQST) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks

Advertisement|Remove ads.